INCY News

Incyte to Present at Upcoming Investor Conferences

Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Incyte to Present at Upcoming Investor Conferences

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

Incyte and Enable Injections Announce Strategic Partnership for enFuse ® On-Body Delivery System

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura ® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer